LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Legend Biotech Corp
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Mar 10, 2026
$18.65+0.17 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $6.89B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$13.31 (−41.65%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Legend Biotech Corp grew revenue 64.0% to $1.03B over the twelve months to Dec 31, 2025. Free cash flow was -$128.80M.
Revenue
$1.03B
+64.0% vs. a year earlier
Operating income
-$136.50M
TTM Q4 2025
Free cash flow
-$128.80M
TTM Q4 2025
EPS, diluted
-$0.81
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Dec 31, 2025
Valuation
- Market cap
- $6.89B
- P/E ratio
- –
- Price to sales
- 6.70
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -1.87%
Fundamentals
- Revenue
- $1.03B
- EPS, diluted
- -$0.81
- Free cash flow
- -$128.80M
- Diluted shares
- 369M
Nine years at a glance
Fiscal years 2017 to 2025, USD
Revenue
$1.03B+64.0% YoY
Gross profit
$631.80M+53.8% YoY
Operating income
-$136.50M
Net income
–
EPS, diluted
-$0.81
Free cash flow
-$128.80M
Reported period